---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-280669"
form_type: "8-K"
ticker: "GRTX"
cik: "0001563577"
company_name: "Galera Therapeutics, Inc."
filed_at: "2022-11-09T23:59:59+00:00"
generated_at: "2026-06-22T01:14:07.822255+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Galera reports Q3 net loss $16M; avasopasem NDA on track by year-end

## Summary
- Net loss of $16M ($0.60/share) vs $22.6M ($0.86) in Q3 2021; cash $42.8M.
- NDA for avasopasem in radiotherapy-induced severe oral mucositis remains on track for submission by end of 2022.
- One-year ROMAN follow-up showed tumor outcomes and overall survival maintained; 50% reduction in chronic kidney disease (10% vs 20% placebo, p=0.0043).
- Meta-analysis of ROMAN and GT-201 (n=551) showed reductions in SOM incidence, duration, onset, and severity.
- Appointed Eugene P. Kennedy, M.D., as Chief Medical Officer, succeeding Jon T. Holmlund who plans to retire.

## SEC filing metadata
- accession: 0001193125-22-280669
- form_type: 8-K
- ticker: GRTX
- cik: 0001563577
- company_name: Galera Therapeutics, Inc.
- filed_at: 2022-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563577/000119312522280669/0001193125-22-280669-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563577/000119312522280669/d419294d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-280669
- JSON: https://secwatch.observer/filing/0001193125-22-280669.json
- Plain text: https://secwatch.observer/filing/0001193125-22-280669.txt

## Key facts
- Earnings Releases
  Galera Therapeutics, Inc. reported the third quarter ended September 30, 2022 results: net income ($16.0) million, or $(0.60) per share, EPS $(0.60) per share.
  - Period: the third quarter ended September 30, 2022
  - Net income: ($16.0) million, or $(0.60) per share
  - EPS: $(0.60) per share
  - Result: reported results
  source text: Galera reported a net loss of ($16.0) million, or $(0.60) per share, for the third quarter of 2022, compared to a net loss of $(22.6) million, or $(0.86) per share, for the same period in 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1563577/000119312522280669/0001193125-22-280669-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.